Drug Trial Radar · NCT07010835
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
189
Planned (sponsor's estimate)
Start
Aug 25, 2025
Primary completion
Jun 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Excyte Biopharma LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of YK012 in participants with Moderate to Severe Systemic Lupus Erythematosus (SLE).
Conditions
- Systemic Lupus Erythematosus (SLE)
Interventions
YK012Drug
YK012 is a bispecific antibody targeting CD19 and CD3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ib dose escalation stage: Dose Limiting Toxicity (DLT)Time frame: From the first infusion of YK012 to Day 28 post first infusion
- Adverse Event (AE)Time frame: From the first infusion of YK012 to the end of trial at 48 weeks
- Severe Adverse Event (SAE)Time frame: From the first infusion of YK012 to the end of trial at 48 weeks
- Ib dose expansion stage and phase II: SRI-4 (Systemic Lupus Erythematosus Responder Index-4) response ratesTime frame: From the first infusion of YK012 to the end of trial at 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.